The Sapheon Closure System Feasibility Study

NCT ID: NCT01603433

Last Updated: 2016-05-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-07-31
• Study Completion Date: 2014-07-31

Brief Summary

This is a single center, prospective, non-randomized, feasibility study for the evaluation of safety, efficacy and performance of the Sapheon™ Closure System for the treatment of incompetent saphenous veins.

Detailed Description

Venous insufficiency of the lower extremities is a very common condition that is influenced by genetic and mechanical factors, and is a chronic and progressive disorder. The primary objectives for this clinical Study are to

1. demonstrate the safety of the Sapheon™ Closure System for the treatment of incompetent saphenous veins,

2. demonstrate the early and late efficacy of The Sapheon™ Closure System for the treatment of incompetent saphenous veins, and

3. demonstrate the satisfactory performance of the Sapheon™ Closure System device components.

Conditions

Venous Insufficiency of Leg

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sapheon™ Closure System

Sapheon™ Closure System for the treatment of incompetent saphenous veins.

Group Type: EXPERIMENTAL

Sapheon™ Closure System

Intervention Type: DEVICE

Sapheon™ Closure System for the treatment of incompetent saphenous veins.

Interventions

Sapheon™ Closure System

Sapheon™ Closure System for the treatment of incompetent saphenous veins.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Males or non-pregnant females ≥21 years of age but <76 years of age.
• Venous reflux disease in the GSV diagnosed by clinical symptoms, with or without visible varicosities, and confirmed by duplex ultrasound imaging.
• Candidate for surgical closure of a segment of the GSV.
• CEAP classification of C2, C3 or C4.
• Ability to walk unassisted.
• Life expectancy of at least 18 months.
• Weight >110 lbs. (50 kg).
• Ability to attend follow-up visits.
• Ability to understand the investigational nature of the treatment, and to provide written informed consent.

Exclusion Criteria

• Previous surgical procedure (surgical, thermal, or chemical ablation) associated with the venous segment to be treated.
• Diameter of index vein (Supine) <3mm or >12 mm in any segment.
• Tortuous GSV, which in the opinion of the Investigator will limit catheter placement.
• Local or systemic infection.
• Insulin dependent diabetes.
• Leg obesity impairing the ability to gain access to the treatment leg, and/or apply sufficient compression for treatment.
• Documented history of superficial or deep thrombophlebitis.
• Varicosities secondary to pelvic or abdominal tumor.
• Significant arterial insufficiency; demonstrated by absence of ankle pulse.
• Known sensitivity to the cyanoacrylate (CA) adhesive or positive reaction just prior to surgery (by injecting a small peripheral vein with the agent). The Study surgeon will judge the need for the injection and the subject's reaction to the injection on clinical grounds.
• Formal duplication of the saphenous trunk in the index vein (Accessory GSV segments allowed).
• Hypercoaguable state.
• Presence of incompetent perforators in the treatment length.
• History of right ventricular failure.
• Significant femoral or popliteal vein insufficiency.
• BMI >35
• Additional procedures in the treatment leg likely required within the six months after the investigational procedure.
• Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment.
• Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the Investigator may prevent safe participation or otherwise render the subject ineligible for the Study.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 76 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Endovascular

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Claudia Bautista, MD

Role: PRINCIPAL_INVESTIGATOR

Clinica Canela

Locations

Clinica Canela

Santo Domingo, , Dominican Republic

Countries

Dominican Republic

References

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. Phlebology. 2015 Jul;30(6):397-404. doi: 10.1177/0268355514532455. Epub 2014 Apr 30.

Reference Type: DERIVED

PMID: 24789750 (View on PubMed)

Other Identifiers

CP-10669-01

Identifier Type: -

Identifier Source: org_study_id